Masked Antibodies & Cytokines As Prodrugs: a landscape analysis of stakeholders, technologies, pipelines, business and financing from an industry perspective

Table of Contents
 

Abbreviations

1 Executive Summary

2 Introduction, Overview & Methodology

3 Stakeholder Analysis
3.1 Overview
3.2 Masking Technology Companies
3.3 Pharma/Biotech Companies Partnered with Masking Technology Companies

4 Profiles of Stakeholders in Masking Technologies

4.1 Profiles of Masking Technology Companies
4.1.1 Accurus Bioscience
4.1.2 Adagene
4.1.3 Amunix Pharmaceuticals
4.1.4 Ascendis Pharma
4.1.5 AskGene Pharma
4.1.6 BioAtla
4.1.7 Bright Peak Therapeutics
4.1.8 CytomX Therapeutics
4.1.9 GlycoNEX
4.1.10 Harpoon Therapeutics
4.1.11 Janux Therapeutics
4.1.12 Maverick Therapeutics
4.1.13 Meditope Biosciences
4.1.14 Molecular Partners
4.1.15 Nektar Therapeutics
4.1.16 Revitope Oncology
4.1.17 SeaGen
4.1.18 Shanghai Affinity Biopharmaceutical
4.1.19 Tansoar Biotech
4.1.20 Trutino Biosciences
4.1.21 Werewolf Therapeutics
4.1.22 Xilio Therapeutics
4.1.23 Zymeworks

4.2 Profiles of Pharma & Biotech Companies with a Stake in Masking Technologies
4.2.1 AbbVie
4.2.2 ADC Therapeutics
4.2.3 Amgen
4.2.4 Astellas Pharma
4.2.5 BeiGene
4.2.6 Boehringer Ingelheim
4.2.7 Bristol Myers Squibb
4.2.8 Exelixis
4.2.9 I-Mab Biopharma
4.2.10 Immunogen
4.2.11 Janssen
4.2.12 Junshi Biosciences
4.2.13 Merck
4.2.14 Mitsubishi Tanabe Pharma
4.2.15 Pfizer
4.2.16 Roche
4.2.17 Takeda Pharmaceutical Co

5 Analysis of Masking Technologies
5.1 Origin of Masking Technologies
5.2 Prodrug Antibody Technologies
5.3 Prodrug Cytokine Technologies
5.4 Prodrug Antibody & Cytokine Technologies

6 Profiles of Masking Technologies

6.1 Masking Technologies Applied Only To Antibodies
6.1.1 Adagene: SAFEbody Technology
6.1.2 BioAtla: Conditionally Active Biologics (CAB)
6.1.3 Harpoon Therapeutics: ProTriTAC Technology
6.1.4 Janux Therapeutics: Tumor Activated T Cell Engager (TRACTr) Technology
6.1.5 Maverick Therapeutics: COBRA Technology
6.1.6 Molecular Partners: Anti-CD3 ProDrug DARPin (CD3-PDD) Technology
6.1.7 Revitope Oncology: PrecisionGATE Technology Platform
6.1.8 Roche: Protease-Activated T-Cell Bispecific (TCB) Antibodies
6.1.9 SeaGen: Coiled-Coil Masking Domain Technology
6.1.10 Tansoar Biotech: Universal Antibody Lock Technology

6.2 Masking Technologies Applied Only To Cytokines
6.2.1 Ascendis Pharma: TransCon Technology
6.2.2 AskGene Pharma: Smartkine Prodrug Technology
6.2.3 Meditope Biosciences: SnAP Technology
6.2.4 Nektar Therapeutics: Kinetically Controlled Prodrug Technology
6-2.5 Trutino Biosciences: On-Demand-Cytokine (ODC) Platform
6.2.6 Werewolf Therapeutics: PREDATOR Technology Platform

6.3 Masking Technologies Applied to Antibodies & Cytokines
6.3.1 Amunix Pharmaceuticals: Pro-XTEN Technology
6.3.2 CytomX Therapeutics: Probody Technology
6.3.3 Xilio Therapeutics: Geographically Precise Solutions (GPS) platform
6.3.4 Zymeworks: PROTECT Technology Platform

7 Analysis of Pipeline and Masked Antibody & Cytokine Prodrug Candidates

7.1 Introduction

7.2 Analysis of the Pipeline of Masked Antibodies
7.2.1 Overview of the Masked Antibody Pipeline
7.2.2 Pipeline of EGFR-Targeted Masked Antibodies
7.2.3 Pipeline of CTLA4-Targeted Masked Antibodies
7.2.4 Pipeline of EpCAM-Targeted Masked Antibodies
7.2.5 Pipeline of Her2-Targeted Masked Antibodies
7.2.6 Pipeline of Masked Antibodies Targeting TROP2, PSMA or B7-H3
7.2.7 Pipeline of Other Masked Antibodies with Designated Targets
7.2.8 Clinical Proof of Mechanism and Concept

7.3 Analysis of the Pipeline of Masked Cytokines
7.3.1 Pipeline of Masked Interleukin-2 Molecules
7.3.2 Pipeline of Masked Interleukin-12 and -15 Molecules
7.3.3 Pipeline of Masked Interferon alpha Molecules

8 Profiles of Masked Antibody & Cytokine Product Candidates

8.1 Masked Immuno-Oncology Antibodies
8.1.1 ADG126
8.1.2 Anti-CD47 Prodrug Antibody
8.1.3 BA3071
8.1.4 BMS-986249
8.1.5 BMS-986288
8.1.6 CX-188
8.1.7 Pacmilimab
8.1.8 PD-L1 x CD28 Costimulatory Bispecific
8.1.9 XTX101

8.2 Masked Antibody-Drug Conjugates
8.2.1 CX-2029
8.2.2 CX-2043
8.2.3 Mecbotamab vedotin
8.2.4 Ozuriftamab vedotin
8.2.5 Praluzatamab ravtansine

8.3 Masked T-Cell Engaging (TCE) Antibodies
8.3.1 AMX-818
8.3.2 BA3182
8.3.3 CX-904
8.3.4 EGFR-TRACTr
8.3.5 EGFR-XPAT
8.3.6 Her2-PROTECT-CD3
8.3.7 HPN601
8.3.8 PSMA-TRACTr
8.3.9 TAK-186
8.3.10 TAK-280
8.3.11 TROP2-TRACTr

8.4 Masked Interleukin-2 (IL-2) Cytokines
8.4.1 Bempegaldesleukin
8.4.2 ODC-IL2
8.4.3 TransCon IL-2 beta/? (beta/gamma)
8.4.4 WTX-124
8.4.5 XTX202

8.5 Masked Interleukin-12 (IL-12) and -15 (IL-15) Cytokines
8.5.1 ASKG215beta (beta) and ASKG215? (gamma)
8.5.2 ProTECT IL-12 Fc
8.5.3 WTX-330

8.6 Masked Interferon (IFN) Cytokines
8.6.1 Dual Masked Interferon alpha2b (alpha2b)
8.6.2 WTX-613

9 Business, Financing & Partnering
9.1 Business
9.2 Financing
9.3 Partnering

10 References
Tables in the Text

ADDENDUM: Competitor Analysis of Masked Antibodies & Cytokines